Actelion creates Vaxxilon together with the Max Planck Society
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion creates Vaxxilon together with the Max Planck Society
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced
the creation of a start-up, together with the Max Planck Society, in the field
of synthetic carbohydrate vaccines.
The new company, Vaxxilon, aims to discover, develop, and commercialize
synthetic carbohydrate vaccines. Vaxxilon has licensed exclusive rights to
multiple preclinical vaccine candidates and additional technologies from Max-
Planck Innovation GmbH, the technology transfer office of the Max Planck
Society.
Actelion is the principal investor and majority shareholder, having made a
funding commitment of up to ?30 million, to be released in tranches over a
period of three to four years.
Jean-Paul Clozel, MD and Chief Executive Officer of Actelion, commented:
"Actelion has had success in advancing the science of the endothelium, and
translating it into therapeutic options for the PAH community. Our long-term
success depends on building additional specialty areas. We have been impressed
by the work performed by the team of Prof. Seeberger and I am very happy that
Actelion can help to translate this work into prophylactic and therapeutic
options."
The first preclinical candidates were discovered and synthesized by Prof. Dr.
Peter Seeberger and his team at the Max Planck Institute of Colloids and
Interfaces in Potsdam, Germany, near Berlin. An additional key component of the
technology was jointly developed by Prof. Seeberger and Prof. Gennaro de Libero
of the University Hospital of Basel. Vaxxilon plans to advance its first vaccine
candidate into man within 3 years.
Jean-Paul Clozel concluded: "Synthetic carbohydrate vaccines represent an
exciting opportunity and have great potential. By creating Vaxxilon with the Max
Planck Society we are building a platform from which synthetic carbohydrate
vaccines could become a commercial reality within the next decade. This
investment represents an innovative way to find synergies between the academic
and industrial worlds."
Prof. Dr. Seeberger, Director at the Max Planck Institute for Colloids and
Interfaces, commented: "I am very proud that the ground-breaking research and
technology from the Max Planck Society in cooperation with my colleague at the
University Hospital of Basel, Prof. Gennaro de Libero, will be advanced in the
form of Vaxxilon. I believe that the speed and flexibility of a small company,
combined with Actelion's financial backing, will allow this novel vaccine
technology to progress and eventually be made available to society quickly and
efficiently. This new class of vaccines promises to be perhaps more efficient,
faster and more reproducible to create and manufacture, and has advantages of
distribution and administration which may improve access to vaccines around the
world."
Vaxxilon will be led by Tom Monroe who has served in multiple and varied roles
of growing responsibility at Actelion over the past 15 years. Four accomplished
chemists from Prof. Seeberger's group will form the initial scientific team at
Vaxxilon, and recruitment will begin quickly for additional experienced
personnel. Vaxxilon, a Swiss limited liability company, will be headquartered in
Reinach, Switzerland, and a research facility will be established in Berlin.
The company will be overseen by a Board of Directors with representatives of
Actelion, Prof. Seeberger, and an independent director as well as an observer
from the Max Planck Society. David Stout, recently elected to the Actelion Board
of Directors, and former President of Pharmaceutical Operations at
GlaxoSmithKline, will serve as chairman.
###
Notes to Editor:
ABOUT SYNTHETIC CARBOHYDRATE VACCINES [1]
Currently available carbohydrate conjugate vaccines are made using
polysaccharides isolated from bacteria. Automated methods to synthesize
carbohydrates rapidly enable the construction of novel vaccines in the
laboratory and accelerate research into effective antigens. These vaccines
combine a synthetic oligosaccharide with a glycolipid CD1d ligand and could
remove the requirement for protein carrier and immune stimulator (adjuvant).
ABOUT VAXXILON
Vaxxilon AG is dedicated to the discovery, development and commercialization of
innovative synthetic carbohydrate vaccines to prevent, first and foremost,
bacterial infections. Vaxxilon has licensed multiple preclinical vaccine
candidates to target pathogens for which there are no approved vaccines, or for
which existing vaccines do not fully meet medical needs. Vaxxilon was created in
2015 by Actelion Ltd and the Max Planck Society. The company is based on the
scientific insights and innovation of Professors Peter Seeberger of the Max
Planck Institute of Colloids and Interfaces and Gennaro de Libero of the
University Hospital of Basel. For more information see www.vaxxilon.com
ABOUT THE MAX PLANCK SOCIETY
The Max Planck Society (MPG) (www.mpg.de) is Germany's leading research
organization. In 83 Max Planck facilities, more than 5,500 scientists and over
7,600 graduate students, undergraduates, student assistants, and visiting
scientists conduct basic research in the natural sciences, life sciences and
humanities. The Max Planck Society was founded in 1948 as a successor to the
Kaiser Wilhelm Society which was established in 1911. Since then, 18 Nobel
laureates have emerged from its ranks. The institutes are of international
repute and attract top researchers from around the world. In addition to five
foreign institutions, the MPG operates another 14 Max Planck Centers with
research institutions such as the Princeton University in the USA, Science Po in
France, the University College London in UK, and the University of Tokyo in
Japan. Equally funded by federal and state governments, the Max Planck Society
has an annual budget of 1.6 billion Euros.
References
1. Marco Cavallari et al. A semisynthetic carbohydrate-lipid vaccine that
protects against S. pneumoniae in mice. Nature Chemical Biology
10,950-956(2014). DOI: 10.1038/nchembio.1650
ACTELION LTD
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our
portfolio of PAH treatments covers the spectrum of disease, from WHO Functional
Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although not available in all countries, Actelion has treatments approved by
health authorities for a number of specialist diseases including Type 1 Gaucher
disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from
systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including Europe, the US, Japan, China, Russia and
Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks
are legally protected.
For further information please contact:
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment
and research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Press Release PDF:
http://hugin.info/131801/R/1931704/694742.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
[HUG#1931704]
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 403213
Anzahl Zeichen: 11136
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 286 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion creates Vaxxilon together with the Max Planck Society"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
